Aurinia Pharmaceuticals Inc. (AUPH) Research
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
Market snapshot
- Symbol
- AUPH
- Price
- $16.46
- Day change
- +1.98%
- Market cap
- $2.1B
- P/E ratio
- 7.31x
- 52-week range
- 7.285-16.88
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 1 month
- Analyst price target
- $12.60
Recent news
- Parabolic AI rally has bulls eyeing a comeback for this one-time meme metal trade
Silver prices surged 7% Monday to the highest since March.
- Why Aurinia Pharmaceuticals Stock Is Surging Monday Morning
The company said Kevin Tang, Aurinia's chair of the board, will succeed Peter Greenleaf as CEO, while Greenleaf will remain on as a consultant to support the transition.
Peer companies
Recent insider activity
- Johnson Craig A — A-Award (23931 shares) on 2026-06-04
- Goetz Kathleen — A-Award (23931 shares) on 2026-06-04
- Nova Tina Susan — A-Award (23931 shares) on 2026-06-04
- Bailey Jeffrey Allen — A-Award (23931 shares) on 2026-06-04
- TANG KEVIN — P-Purchase (206005 shares) on 2026-06-02
Open Aurinia Pharmaceuticals Inc. (AUPH) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.